| Autor: |
Sahin IH; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA. ihsahin@emory.edu., Akce M; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA., Alese O; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA., Shaib W; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA., Lesinski GB; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA., El-Rayes B; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA., Wu C; Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA. |
| Abstrakt: |
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden and tumour-infiltrating lymphocytes. Studies have shown a sustained clinical response to immune checkpoint inhibitors with dramatic clinical improvement in patients with MSI-H/MMR-D CRC. However, the observed response rates range between 30% and 50% suggesting the existence of intrinsic resistance mechanisms. Moreover, disease progression after an initial positive response to immune checkpoint inhibitor treatment points to acquired resistance mechanisms. In this review article, we discuss the clinical trials that established the efficacy of immune checkpoint inhibitors in patients with MSI-H/MMR-D CRC, consider biomarkers of the immune response and elaborate on potential mechanisms related to intrinsic and acquired resistance. We also provide a perspective on possible future therapeutic approaches that might improve clinical outcomes, particularly in patients with actionable resistance mechanisms. |
Full text from SpringerLink